期刊
JOURNAL FOR IMMUNOTHERAPY OF CANCER
卷 4, 期 -, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1186/s40425-016-0175-4
关键词
Sipuleucel-T; Tumor vaccine; Prostate cancer; TCR sequencing; T-cell diversity
资金
- Department of Defense Congressionally Directed Medical Research Program [W81XWH-15-1-0492]
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor V beta CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据